Clinical Trials Logo

Large B-cell Lymphoma clinical trials

View clinical trials related to Large B-cell Lymphoma.

Filter by:

NCT ID: NCT05326243 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Start date: May 31, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multiple center, non-randomized, open-label, phase 1/2 study. The primary objective of Phase 1 is to evaluate the safety of PL001 and find the recommended Phase 2 dose (RP2D). The objective of Phase 2 is to evaluate the safety and efficacy of CD19 CAR-T(known as PL001).

NCT ID: NCT05020678 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Start date: August 20, 2021
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)

NCT ID: NCT04889716 Recruiting - Clinical trials for Large B-cell Lymphoma

CAR-T Followed by Bispecific Antibodies

Start date: November 5, 2021
Phase: Phase 2
Study type: Interventional

The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).

NCT ID: NCT04250324 Recruiting - Clinical trials for Large B-cell Lymphoma

Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma

Start date: November 19, 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, dose-escalation phase 1 study to determine the Safety and Efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma subjects.

NCT ID: NCT03960840 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL

Start date: June 26, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).

NCT ID: NCT03188198 Recruiting - Clinical trials for Large B Cell Lymphoma

Risk Adapted Therapy in Diffuse Large B Cell Lymphoma

Start date: June 1, 2016
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma.